Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 14/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15565297 | 1.00 | ENPP2 (0.46) | ENPP2LPAR1S1PR5SCN9APIM1 | |
| SCHEMBL15599909 | 0.91 | ENPP2 (0.39) | ENPP2LPAR1S1PR5SCN9A | |
| SCHEMBL15565633 | 0.88 | ENPP2 (0.44) | ENPP2LPAR1 | |
| SCHEMBL15565631 | 0.88 | ENPP2 (0.44) | ENPP2LPAR1 | |
| SCHEMBL15600015 | 0.86 | ENPP2 (0.38) | ENPP2LPAR1S1PR5SCN9A | |
| SCHEMBL15565311 | 0.82 | ENPP2 (0.43) | ENPP2LPAR1S1PR5SCN9A | |
| SCHEMBL15565308 | 0.82 | ENPP2 (0.43) | ENPP2LPAR1S1PR5SCN9A | |
| SCHEMBL20403951 | 0.81 | ENPP2 (0.45) | ENPP2LPAR1S1PR5 | |
| SCHEMBL15599982 | 0.81 | ENPP2 (0.47) | ENPP2LPAR1S1PR5SCN9A | |
| SCHEMBL15599971 | 0.80 | ENPP2 (0.48) | ENPP2LPAR1S1PR5SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879673-B1 | 1,5,6-substituted naphthalene derivatives as sphingosine 1 phosphate (S1P) receptor and/or autotaxin (ATX) modulators for treating inflammatory and autoimmune disorders | BIOGEN MA INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9499485-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150183741-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2015-07-02 | — | — | US | disclosed |
| EP-2879673-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014025709-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183741-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | ENPP2 1/4885LPAR1 8/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.